StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Lokelma (sodium zirconium cyclosilicate) by Quarter

Lokelma (sodium zirconium cyclosilicate) — US YoY (%) (%)

QuarterlyAnnual

AstraZeneca Lokelma (sodium zirconium cyclosilicate): 13.0% in Q2 2026, down 5.0 pts from a year earlier.

Latest, Q2 2026
13.0%
Period ended Jun 30, 2026
Change on a year earlier
-5.0 pts
18.0% in Q2 2025
History
19 quarters
Since Q4 2021
Sources
19
Documents cited below

Where the Q2 2026 figure comes from

“|| Lokelma | 221 | | 26 | | 26 | | 85 | | 13 | | 48 | | 47 | | 40 | | 47 | | 54 | | 46 | | 41 | | 12 | | 22”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLokelma (sodium zirconium cyclosilicate) — US YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202613.0%-5.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202614.0%-19.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20250.0%-30.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202525.0%-3.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202518.0%-11.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202533.0%+40.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202430.0%+9.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202428.0%+13.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202429.0%+3.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-7.0%-52.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202321.0%-19.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202315.0%-22.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202326.0%-29.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202345.0%-17.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202240.0%-30.0 ptsForm 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202237.0%–Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Lokelma (sodium zirconium cyclosilicate) (%), quarterly Q4 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-lokelma-us-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?